Halozyme Therapeutics | HALO - Ebitda


Halozyme Therapeutics reported $328.81M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 3.86B 1.28B Mar/2026
Baxter International USD 309M 756M Mar/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
DBV Technologies USD -45.9M 12.42M Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
MannKind USD 2.93M 5.98M Mar/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
United Therapeutics USD 355M 11.1M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024